![Boston_H_color[33632]_edited.png](https://static.wixstatic.com/media/e60c5c_0b72738a80554196840094a8e387c5ed~mv2.png/v1/fill/w_338,h_77,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Boston_H_color%5B33632%5D_edited.png)
Tue, Nov 10
|Webinar
New Evidence in First-Line AML and Exploring Outcomes with Fixed-Duration Treatment in CLL
Time & Location
Nov 10, 2020, 5:00 PM
Webinar
About The Event
Tuesday, November 10, 2020, 5:00 PM ET
Donna Adams, NP Adult Oncology Nurse Practitioner, Division of Cellular Therapeutics, APP Team Lead for Hematologic Malignancies, Duke University Health Systems, Durham, NC
Corinne Williams, PA-C Robert H Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital, Chicago, IL
REGISTER via link below:
https:// abbvie.meintl.com/00071-OB24-20
DURING THIS INTERACTIVE PROGRAM WE WILL:
• Recognize VENCLEXTA as a BCL-2 inhibitor for 1L AML, and 1L and R/R CLL • Review the phase 3 efficacy and safety outcomes of VENCLEXTA + azacitidine from the pivotal VIALE-A study
for patients with 1L AML, ineligible for intensive induction chemotherapy due to age or comorbidities • Explore the efficacy and safety outcomes of VENCLEXTA’s chemo-free, fixed duration CLL regimens